[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-unresectable-esophageal-squamous-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-unresectable-esophageal-squamous-cell-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,73,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100632884","phase-2-intensive-nutritional-support-in-conversion-therapy-for-locally-advanced-unresectable-escc-100632884",false,"NCT07519486","Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC","A Prospective Randomized Controlled Clinical Trial of Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","INS-ESCC-CT","Inclusion Criteria:\n\nPathologically confirmed Esophageal Squamous Cell Carcinoma (ESCC). Aged 18-80 years, regardless of gender. ECOG Performance Status (PS) 0-2, and weight loss \\\u003C 10% within the past 6 months.\n\nConfirmed locally advanced unresectable ESCC according to NCCN Guidelines (Version 2026.1).\n\nPlanned to receive surgery after completion of conversion therapy, with no surgical contraindications.\n\nTreatment-naive: No prior anti-tumor therapy for ESCC, including radiotherapy, chemotherapy, or surgery.\n\nPresence of measurable lesion(s) according to RECIST 1.1. Expected survival ≥ 3 months. Able to swallow and tolerate oral medications. Adequate organ function (blood counts, biochemistry, and coagulation parameters meeting protocol requirements).\n\nWomen of childbearing age and men must agree to use effective contraception during the study and for 6 months after completion.\n\nVoluntary participation with signed informed consent and good compliance.\n\nExclusion Criteria:\n\nPresence of esophageal-mediastinal fistula and\u002For tracheoesophageal fistula, or tumor invasion of major vessels with risk of fatal hemorrhage.\n\nHistory of other malignant tumors within the past 5 years. Current or prior use of immunosuppressants or systemic steroids (\\>10 mg\u002Fday prednisone equivalent) within 2 weeks prior to first dose.\n\nActive autoimmune disease or history of autoimmune disease requiring systemic treatment.\n\nKnown immunodeficiency history, including HIV infection, organ transplant, or bone marrow transplant.\n\nUncontrolled concurrent diseases (e.g., uncontrolled hypertension, unstable angina, recent myocardial infarction, or severe infections).\n\nActive tuberculosis (TB) or history of TB without standardized treatment. Active Hepatitis B (HBV) or Hepatitis C (HCV) infection. Complete inability to take oral enteral nutrition due to esophageal stenosis. History or current presence of interstitial pneumonia or interstitial lung disease.\n\nUncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n\nSignificant gastrointestinal disorders with severe diarrhea (CTCAE \\> Grade 2). Pregnant or lactating women. Participation in other clinical trials within 30 days prior to enrollment.","ALL","18 Years","80 Years",{"count":21,"type":22},118,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Malnutrition is highly prevalent in patients with upper gastrointestinal tumors, which may negatively impact treatment tolerance and anti-tumor immune responses. This study aims to evaluate the efficacy and safety of intensive enteral nutritional support in patients with locally advanced unresectable esophageal squamous cell carcinoma (ESCC) undergoing conversion therapy. Participants receiving PD-1 inhibitors combined with chemotherapy will be randomly assigned to either intensive nutritional support or standard care. The primary goal is to determine if intensive nutritional support can improve the pathological complete response (pCR) rate after subsequent surgery.",[28,29],"Esophageal Squamous Cell Carcinoma","Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma",[31,32,33],"Esophageal Neoplasms","Nutritional Support","Neoadjuvant Therapy","RECRUITING","2026-04-10",{"date":37,"type":38},"2026-04-15","ACTUAL",{"date":40,"type":22},"2026-04",{"date":42,"type":22},"2028-03",{"name":44,"class":45},"Sichuan University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100633700","phase-2-short-course-definitive-chemoradiotherapy-combined-with-adjuvant-or-concurrent-plus-adjuvant-camrelizumab-for-locally-advanced-unresectable-esophageal-squamous-cell-carcinoma-100633700","NCT07530094","Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Multi-Cohort Phase II Clinical Study (STELLAR01)","STELLAR01","Inclusion Criteria:\n\n1. The patient or their legal representative is able to sign the written informed consent form and understands and agrees to comply with the study requirements;\n2. Age ≥ 18 years and \\\u003C 75 years at the time of signing the informed consent form, regardless of gender;\n3. Histologically confirmed esophageal squamous cell carcinoma, confirmed by imaging examinations such as CT, MRI, or PET-CT as locally advanced unresectable ESCC (medically unsuitable for surgery or refusal of surgical intervention), and suitable for cCRT, including: stages II-IVa and certain cases of stage IVb (involving only supraclavicular lymph node metastasis) (AJCC version 8 ) meeting the criteria;\n4. Estimated life expectancy of at least 6 months;\n5. ECOG performance status score of 0-2;\n6. Presence of measurable and\u002For non-measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);\n7. No prior systemic anti-tumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy, local therapy, or other investigational treatments);\n8. Adequate organ function, as indicated by laboratory test results obtained within 14 days prior to enrollment:\n9. a. Achieved without the need for blood transfusion, growth factor therapy, or other supportive medications that significantly affect neutrophil count, platelet count, or hemoglobin within ≤ 14 days before sample collection during screening: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; platelet count ≥ 100 × 10⁹\u002FL; hemoglobin ≥ 90 g\u002FL;\n10. b. Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration equation (Appendix 9);\n11. c. Serum total bilirubin ≤ 1.5 × ULN (for patients with Gilbert's syndrome, total bilirubin must be ≤ 3 × ULN);\n12. d. Aspartate aminotransferase and ALT \\\u003C 3 × ULN;\n13. For patients with inactive\u002Fasymptomatic carriers, chronic or active HBV infection, the following criteria must be met:\n14. HBV DNA \\\u003C 500 IU\u002FmL (or 2500 copies\u002FmL) during screening;\n15. Note: Patients with positive hepatitis B surface antigen or detectable HBV DNA should be managed according to treatment guidelines. Patients receiving antiviral therapy during screening must have undergone treatment for \\> 2 weeks prior to enrollment;\n16. Female patients of childbearing potential must voluntarily agree to use highly effective contraception during the study period, for ≥ 120 days after the last dose of camrelizumab or placebo, and for ≥ 180 days after the last dose of chemoradiotherapy, and must have a negative urine or serum pregnancy test result within ≤ 7 days prior to enrollment;\n17. Male patients who are not sterilized must voluntarily agree to use highly effective contraception during the study period, for ≥ 120 days after the last dose of camrelizumab or placebo, and for ≥ 180 days after the last dose of chemoradiotherapy.\n\nExclusion Criteria:\n\nHere is the translation of the exclusion criteria into English:\n\n1. History of other malignancies;\n2. History of fistula caused by primary tumor infiltration;\n3. Patients at high risk of esophageal fistula or with signs of esophageal perforation;\n4. History of esophageal cancer surgery;\n5. Poor nutritional status, with BMI less than 18.5 kg\u002Fm², or PG-SGA score ≥ 9;\n6. Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or medical intervention (within 2 weeks prior to randomization);\n7. Known intolerance or resistance to the chemotherapy regimen specified in the study protocol;\n8. Prior receipt of any other anti-tumor therapy for ESCC (e.g., therapies targeting PD-1, PD-L1, PD-L2, or other tumor immunotherapies, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor treatments);\n9. Patients with active autoimmune disease or a history of autoimmune disease that may relapse;\n10. Note: Patients with the following conditions are not excluded and may proceed to further screening:\n\na. Controlled type I diabetes; b. Hypothyroidism (controlled with hormone replacement therapy only); c. Controlled celiac disease; d. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia); e. Any other disease that is not expected to relapse in the absence of external triggers; k. Presence of other active malignancies within ≤ 2 years prior to enrollment, except for the specific cancer under study in this trial and locally recurrent cancers that have been cured (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast); l. Any condition requiring systemic treatment with corticosteroids (dose \\> 10 mg\u002Fday of prednisone or equivalent) or other immunosuppressive agents within ≤ 14 days prior to randomization;\n\nNote: Patients who have currently or previously used any of the following steroid regimens are not excluded:\n\na. Adrenal replacement steroids (prednisone ≤ 10 mg\u002Fday or equivalent); b. Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; c. Short-term (≤ 7 days) prophylactic use of corticosteroids (e.g., for prevention of contrast agent allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reaction caused by contact allergens); m. Presence of uncontrolled diabetes, laboratory test abnormalities for potassium or sodium \\> Grade 1 despite standard medical therapy, or hypoalbuminemia ≥ Grade 3 within ≤ 14 days prior to enrollment; n. History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases including pulmonary fibrosis, acute lung diseases, etc.; o. Presence of severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy (including tuberculosis infection, etc.) within 14 days prior to enrollment; Note: Patients with chronic HBV or HCV infection are permitted to receive antiviral therapy; p. Known history of HIV infection; q. Major surgery performed within ≤ 28 days prior to enrollment; Note: Minimally invasive procedures (e.g., peripherally inserted central catheter \\[PICC\\]) are not considered major surgery; r. Prior allogeneic stem cell transplantation or organ transplantation; s. Presence of any of the following cardiovascular risk factors:\n\n1. Cardiac chest pain occurring within ≤ 28 days prior to randomization, defined as moderate pain limiting instrumental activities of daily living;\n2. Symptomatic pulmonary embolism occurring within ≤ 28 days prior to randomization;\n3. Acute myocardial infarction occurring within ≤ 6 months prior to randomization;\n4. History of heart failure reaching New York Heart Association (NYHA) Class III or IV within ≤ 6 months prior to randomization;\n5. Ventricular arrhythmia ≥ Grade 2 occurring within ≤ 6 months prior to randomization;\n6. Cerebrovascular accident occurring within ≤ 6 months prior to randomization;\n7. Uncontrolled hypertension despite antihypertensive medication, i.e., systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, within ≤ 28 days prior to randomization;\n8. Syncope or seizure occurring within ≤ 28 days prior to randomization;\n\nt. History of severe hypersensitivity reaction to other monoclonal antibodies or to cisplatin or paclitaxel; u. Receipt of any chemotherapy, immunotherapy (e.g., interleukins, interferons, thymosins, etc.), or any investigational treatment within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug; v. Use of herbal medicines for cancer control within 14 days prior to the first dose of study drug; w. Patients with toxicities from prior anti-tumor therapy that have not recovered to baseline or stable levels, unless considered as adverse events without safety risks (e.g., alopecia, neuropathy, specific laboratory abnormalities); x. Receipt of live vaccine within ≤ 28 days prior to randomization; Note: Seasonal influenza vaccines are typically inactivated vaccines and are permitted. Intranasal vaccines are live vaccines and are not permitted; y. Presence of underlying diseases (including laboratory abnormalities), alcohol or substance abuse or dependence that may interfere with study drug administration, affect interpretation of drug toxicity or adverse events, or compromise the patient's compliance with study procedures; z. Concurrent participation in another therapeutic clinical trial; aa. Other factors that, in the investigator's judgment, may necessitate premature termination of the study participation (e.g., prisoners or individuals under involuntary detention; individuals detained involuntarily for treatment of psychiatric or physical illnesses such as infectious diseases).","75 Years",{"count":57,"type":22},98,[25],"This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.",[29],[62,63,64],"esophageal carcinoma","Definitive Chemoradiotherapy","immunotherapy","2026-04-08",{"date":37,"type":38},{"date":68,"type":38},"2025-12-01",{"date":70,"type":22},"2027-12-01",{"name":72,"class":45},"Ning Jiang, M.D.\u002FPh.D.",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":46},"100626424","phase-2-exploratory-clinical-trial-of-oral-paclitaxel-plus-radiotherapy-in-patients-with-locally-advanced-unresectable-esophageal-squamous-cell-carcinoma-100626424","NCT07435454","Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Histologically confirmed locally advanced unresectable esophageal squamous cell carcinoma (cTXN+M0 or cT2-T4aNXM0).\n2. Considered eligible for definitive chemoradiotherapy.\n3. Age ≥ 70 years and\u002For intolerant to intravenous chemotherapy due to comorbidities, with severe dysphagia\u002Ffeeding obstruction.\n4. Disease evaluable by qualitative radiologic assessment per the local investigator.\n5. Not eligible for curative surgery.\n6. Adequate hematologic function, defined as: ANC ≥ 1500\u002FμL, platelet count ≥ 100,000\u002FμL, and hemoglobin ≥ 9.0 g\u002FdL or ≥ 5.6 mmol\u002FL.\n7. Adequate renal function, defined as: creatinine ≤ 1.5 × ULN; or for patients with creatinine \\> 1.5 × ULN, measured or calculated creatinine clearance ≥ 60 mL\u002Fmin.\n8. Adequate hepatic function, defined as: total bilirubin ≤ 1.5 × ULN; or for patients with total bilirubin \\> 1.5 × ULN, direct bilirubin ≤ ULN provided ALT\u002FAST ≤ 2.5 × ULN and albumin ≥ 3.0 g\u002FdL.\n9. Adequate coagulation function, defined as: INR ≤ 1.5 × ULN, unless the patient is on anticoagulant therapy with PT or aPTT within the therapeutic range.\n10. Negative urine or serum pregnancy test within 24 hours prior to the first dose of study intervention.\n11. Voluntary participation in the study, signed written informed consent, good compliance, and willingness to comply with follow-up procedures.\n\nExclusion Criteria:\n\n1. Direct tumor invasion into adjacent organs, such as the aorta or trachea (i.e., T4b disease).\n2. Prior chemotherapy or radiotherapy for esophageal cancer.\n3. Any prior systemic anticancer therapy for esophageal cancer.\n4. Major surgery other than feeding tube insertion, open biopsy, or significant trauma within 28 days before randomization, or anticipated major surgery during study treatment.\n5. History of other malignancy within the past 5 years, except carcinoma in situ of the cervix or basal cell carcinoma.\n6. Gastric fistula or esophageal fistula.\n7. Active infection requiring systemic therapy.\n8. Known history of HIV, HBV, or HCV infection.\n9. Participation in a study of an investigational drug or device within 4 weeks prior to the first study treatment.\n10. History of non-infectious pneumonitis requiring corticosteroid therapy, or current pneumonitis.\n11. Known hypersensitivity to any study drug.\n12. Inability or unwillingness to comply with protocol requirements as assessed by the investigator.","70 Years",{"count":81,"type":22},22,[25],"This study aims to investigate the safety and efficacy of oral paclitaxel combined with radiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.",[29],[62,86,87],"oral paclitaxel","radiotherapy","2026-02-25",{"date":90,"type":38},"2026-02-27",{"date":68,"type":38},{"date":70,"type":22},{"name":94,"class":45},"Jiangsu Cancer Institute & Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100601618","phase-2-a-phase-ii-clinical-study-of-induction-adebrelimab-combined-with-chemotherapy-followed-by-concurrent-chemoradiotherapy-for-locally-advanced-unresectable-esophageal-squamous-cell-carcinoma-escc-100601618","NCT07112833","A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","Inclusion Criteria:\n\n* 1\\. Age 18-75 years old, both men and women; 2. Histopathology confirmed esophageal squamous cell carcinoma, locally advanced: T1N+M0, T2-4bNxM0; 3. The surgeon assesses that surgery is not feasible or the patient refuses surgical treatment; 4. If technically feasible, all patients are recommended to have local staging determined by endoscopic ultrasound (EUS); The endoscopic examination report or gastrointestinal (GI) clinical records should clearly indicate the T and N stages; Perform PET-CT examination; 5. Except for basal or squamous cell skin cancer, bladder cancer in situ or cervical cancer, there is no history of malignant tumor within 5 years; Patients with malignant tumors who have undergone surgical treatment in the past and those who have survived disease-free for more than 5 years meet the inclusion criteria; 6. Have not received any systemic anti-tumor treatment in the past (systemic chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) 7. At least one measurable lesion（According to RECIST 1.1：The long diameter of the measurable lesion on CT scan is ≥10 mm or the short diameter of the enlarged lymph node is ≥15 mm）; 8. ECOG: 0\\~1; 9. Expected survival period ≥ 12 weeks; 10. Major organ function has to meet the following certeria: (1) Blood routine examination: 1. HB≥90g\u002FL; 2. ANC ≥ 1.5 × 109 \u002F L; 3. PLT ≥ 100 × 109 \u002F L; (2) Biochemical examination: a. ALT and AST \\\u003C 2.5XULN; b. TBIL ≤ 1.5XULN; c. Cr ≤ 1.5XULN; 11. Left ventricular ejection fraction (LVEF) ≥50%; 12. Female subjects of childbearing age or male who undergo non-surgical sterilization must agree to use at least one medically approved contraceptive measure (such as intrauterine device, contraceptive pill) for contraception during the study treatment period and within 3 months after the end of the study treatment period. For female subjects of childbearing age who undergo non-surgical sterilization, the serum HCG test must be negative within 7 days before the first administration. 13. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.\n\nExclusion Criteria:\n\n* 1\\. Previous history of esophageal cancer surgery； 2. Higher risk of esophageal perforation or fistula； 3. Received systemic immunosuppressive therapy within 14 days prior to the first study medication； 4. Known or suspected to have interstitial pneumonia; Other moderate to severe lung diseases that may seriously affect respiratory function; 5. The patient has any active autoimmune disease or history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, enteritis, systemic lupus erythematosus, rheumatoid arthritis; patients with vitiligo, Asthma has been completely relieved in childhood, and patients who do not need any intervention after adulthood can be included; asthma patients who require bronchodilators for medical intervention cannot be included); 6. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥ 1000 copies\u002Fml or 500IU\u002Fml), hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method)； 7. Within 6 months, cerebral vascular accidents (including transient ischemic attacks or symptomatic pulmonary embolism) occur; 8. History of cardiovascular disease with significant clinical significance, including but not limited to: (1) congestive heart failure (NYHA grade\\>2); (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within 3 months; (4) Any supraventricular arrhythmias or ventricular arrhythmias that require treatment or intervention; 9. Severe infections within 4 weeks before study drug administration, or active infection with CTCAE ≥ 2 grade treated with antibiotics within 2 weeks before study drug administration; 10. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 11. History of psychiatric drugs abuse and can't quit or patients with mental disorders; 12. The researchers think inappropriate.",{"count":102,"type":22},36,[25],"This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT or RECIST1.1 assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.",[29],"NOT_YET_RECRUITING","2025-08-01",{"date":109,"type":38},"2025-08-08",{"date":111,"type":22},"2025-08-10",{"date":113,"type":22},"2027-12-31",{"name":115,"class":45},"Hebei Medical University Fourth Hospital"]